June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Corneal Toxicity of Antibody Drug Conjugate Chemotherapeutics
Author Affiliations & Notes
  • Alicia Morgan Eby
    Ophthalmology, Kresge Eye Institute, Royal Oak, Michigan, United States
  • Rabeea Khan
    Ophthalmology, Kresge Eye Institute, Royal Oak, Michigan, United States
  • Monica Ray
    Ophthalmology, Kresge Eye Institute, Royal Oak, Michigan, United States
  • Lance Heilbrun
    Karmanos Cancer Institute, Detroit, Michigan, United States
  • Cheryl Milanovic
    Ophthalmology, Kresge Eye Institute, Royal Oak, Michigan, United States
  • Jackson Jessica
    Ophthalmology, Kresge Eye Institute, Royal Oak, Michigan, United States
  • Mark McDermott
    Ophthalmology, Kresge Eye Institute, Royal Oak, Michigan, United States
  • Elisabeth Heath
    Karmanos Cancer Institute, Detroit, Michigan, United States
  • Footnotes
    Commercial Relationships   Alicia Eby, None; Rabeea Khan, None; Monica Ray, None; Lance Heilbrun, None; Cheryl Milanovic, None; Jackson Jessica, None; Mark McDermott, None; Elisabeth Heath, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2645. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alicia Morgan Eby, Rabeea Khan, Monica Ray, Lance Heilbrun, Cheryl Milanovic, Jackson Jessica, Mark McDermott, Elisabeth Heath; Corneal Toxicity of Antibody Drug Conjugate Chemotherapeutics. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2645.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Antibody drug conjugates (ADCs) are a novel chemotherapeutic drug class composed of a chemotherapeutic agent attached to a targeting antibody via a linker protein, and show great promise in the treatment of a variety of cancers. ADCs are approved in the treatment of breast and lung cancer and trials are underway for prostate, renal, and urological cancers. However, there have been ocular side-effects and complications observed in a significant number of patients on ADCs, which in some cases have even led to discontinuation of the drug1. This retrospective review aims to report the ocular side effects of these novel chemotherapeutic agents.

Methods : Using a database of patients that have received treatment with ADC’s at Karmanos Cancer Institute and undergone ocular examination at Kresge Eye Institute, we collected information including: ocular symptoms, drug status, visual acuity, manifest refraction, slit lamp examination, Schirmer’s test, slit lamp corneal photography, and Pentacam topography.

Results : Of the 28 patients examined on ADC therapy, we report ocular toxicity in 9 patients (32%). The ocular toxicity localized to the corneal surface, and consisted of a characteristic form of annular keratitis in all patients. Additionally, the keratitis was found to resolve with cessation of the drug. We also report changes in vision and refraction consistent with a hyperopic shift that was found to be reversible with cessation of the drug.

Conclusions : ADCs have been found to be associated with corneal toxicity, suspected to be a direct effect of the chemotherapeutic agent on the corneal stem cells3. In patients who have keratitis that is affecting their vision and significantly limiting their quality of life, we have been forced to discontinue the ADC even though it may have been extremely effective in treating their cancer. Clinically, this keratitis has been found to resolve spontaneously with drug cessation without lasting impact on the patients vision. Given that ocular toxicity is a common side effect of ADC therapy, and can even lead to discontinuation of the drug, further studies are necessary to characterize the nature of the toxicity and to develop a recommended threshold for drug discontinuation.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×